Novo Nordisk
-
Pharma, Artificial Intelligence, BioPharma
Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
-
Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Novo Nordisk Aims to Succeed Where Sanofi Faltered Drugging a Weight-Loss Target
Novo Nordisk isn’t putting all of its weight loss drug hopes in the same basket. Its acquisition of Inversago Pharma for up to $1 billion will bring a biotech whose lead drug candidate has early clinical trial data showing significant weight loss.
-
Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
-
How One Healthcare Exec Wants Employers To Tackle Obesity
Employers should be looking at obesity as a chronic condition and focus on weight management solutions over weight loss solutions, said Parin Chikani, medical account director for managed markets at Novo Nordisk. He made these comments Tuesday at the Midwest Business Group on Health conference in Chicago.
-
Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
-
California lawsuit targets insulin costs as Biden also takes aim in SOTU
High prices have drawn other critics, as well, including President Joe Biden. He renewed his call for a broad price cap during his annual State of the Union address. Pharma companies insist they have been part of the solution.
-
Novo Nordisk’s Diabetes Pill Rybelsus Gets FDA O.K. as First-Line Therapy
The FDA approved a change in Rybelsus’s label, allowing the drug to be used as an initial therapy for type 2 diabetes patients. The once-daily pill has already become a blockbuster product for Novo Nordisk.
-
Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug
Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule blocks a protein that has become an attractive target for big pharmaceutical companies, such as Roche and Novartis.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Novo Nordisk to buy sickle cell disease biotech Forma Therapeutics in $1.1B deal
Novo Nordisk announced that it will buy Forma Therapeutics, a clinical-stage biotech focused on rare hematologic diseases, in an deal valued at $1.1 billion. The deal is the second billion-dollar sickle cell disease deal the pharmaceutical industry has seen in the last 30 days — Pfizer forked over $5.4 billion in August to buy Global Blood Therapeutics.
-
Why obesity intervention needs to be a bigger part of chronic disease care
Obese patients are more at risk for diabetes, cardiovascular disease, certain cancers and mortality than patients who maintain a healthy weight, and obese patient who develop these chronic conditions usually have more complications. That is why providers and payers must integrate more weight loss strategies in chronic condition care, panelists argued at a Tuesday panel hosted by the Chamber of Commerce.
-
Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dicerna Pharma
The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The most advanced therapy from that alliance is on track to reach the clinic in 2022.
-
Novo Nordisk cardio push picks up Phase 2-ready Prothena drug in $100M deal
Novo Nordisk is paying $100 million up front to acquire an experimental Prothena drug being developed to treat heart problems stemming from a misfolded protein. The deal is part of a broader strategy to expand into drugs for cardiovascular disease.
-
Walmart rolls out discounted insulin, but patients still grapple with high prices
Walmart struck a deal with Novo Nordisk to offer a heavily discounted, private-label version of its fast-acting analog insulin. But it still doesn’t solve the pricing problems patients have faced, with insulin costs skyrocketing in recent years.
-
Covid-19 serves as catalyst for effort to diversify clinical trial enrollment
Covid-19 showed how technology can upend the old ways of clinical trials. Panelists at MedCity’s INVEST conference said it’s highlighting the importance of improving clinical trial diversity so that tests of new therapies and vaccines reflect the population of patients that they will treat in the real world.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
